Targets › NS3
1 program from 1 company in 1 trial: 1 Phase 4; Infectious disease; next expected readout Jul 2029.
Open in Phaseline: the race on NS3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Kirby Institute | Pibrentasvir Nonstructural protein 5A inhibitor | NS3, NS5A | Phase 4 | Hepatitis C | Jul 2029 |
Hepatitis C (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.